The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. cours. OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation. 3.3 Analyse von Lactose, Glucose und Galactose: Problematik „Lactoseintoleranz" 95 3.4 Trennung von Zuckern aus Honig und Marmeladen an Aminophasen 105 3.5 Bestimmung von niederen organischen Säuren in verschiedenen Fermentationsmedien 113 3.6 Analyse von Citronen- und Ascorbinsäure in OSE IMMUNO Cours Action OSE, Cotation Bourse Euronext Paris - Boursorama OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global ... OSE Immunotherapeutics Sylvie Détry sylvie.detry@ose-immuno.com +33 153 198 757 Investor Relations Thomas Guillot thomas.guillot@ose-immuno.com +33 607 380 431 OSE Immunotherapeutics to Present New Clinical and Preclinical Data at ... OSE Immunotherapeutics to Host an "Immuno-Oncology R&D Day" On October ... Ose immuno : L'essai sur le vaccin anti-Covid d'OSE Immuno suspendu ... With ISO . The company's immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto . OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. Data presented at the 36th Annual Society for Immunotherapy of Cancer (SITC) MeetingNANTES, France, Nov. 16, 2021 (GLOBE NEWSWIRE) -- November 16, 2021, 7:30 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented new clinical and translational data on Tedopi® (neoepitope-based cancer vaccine) in non-small cell lung cancer and the latest data from BiCKI®-IL-7 . OSE: OSE Immuno Stock Price Quote - EN Paris - Bloomberg